PROBIOTEC LIMITED (PBP)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

PBP - PROBIOTEC LIMITED

Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: 2.53
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$2.85

18 Apr
2024

0.010

OPEN

$2.86

0.35%

HIGH

$2.86

27,182

LOW

$2.84

TARGET
$3.00 5.3% upside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . ARX . AVH . BIO . BOT . CSL . CUV . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MDC . MSB . MVP . MYX . NEU . NXS . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
PBP: 1
Title FY22
Actual
FY23
Actual
FY24
Forecast
FY25
Forecast
EPS (cps) xxx N/A 15.1 xxx
DPS (cps) xxx N/A 7.3 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A 18.8 xxx
Dividend Yield xxx N/A 2.6% xxx
Div Pay Ratio(%) xxx N/A 48.3% xxx

Dividend yield today if purchased 3 years ago: 2.98%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

2.29

Estimated Dividend Growth
(Average Of Past Three Years)

 %

Amount Invested

Tell Me The Dividend After This Many Years

Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 22/10 - ex-div 3c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201820192020202120222023
EPS Basic xxxxxxxxxxxxxxx13.6
DPS All xxxxxxxxxxxxxxx6.5
Sales/Revenue xxxxxxxxxxxxxxx214.0 M
Book Value Per Share xxxxxxxxxxxxxxx107.2
Net Operating Cash Flow xxxxxxxxxxxxxxx17.2 M
Net Profit Margin xxxxxxxxxxxxxxx5.15 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201820192020202120222023
Return on Capital Employed xxxxxxxxxxxxxxx13.26 %
Return on Invested Capital xxxxxxxxxxxxxxx7.71 %
Return on Assets xxxxxxxxxxxxxxx4.66 %
Return on Equity xxxxxxxxxxxxxxx13.26 %
Return on Total Capital xxxxxxxxxxxxxxx11.95 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx4.1 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201820192020202120222023
Short-Term Debt xxxxxxxxxxxxxxx53 M
Long Term Debt xxxxxxxxxxxxxxx35 M
Total Debt xxxxxxxxxxxxxxx88 M
Goodwill - Gross xxxxxxxxxxxxxxx65 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx14 M
Price To Book Value xxxxxxxxxxxxxxx2.61

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201820192020202120222023
Capex xxxxxxxxxxxxxxx10.1 M
Capex % of Sales xxxxxxxxxxxxxxx4.74 %
Cost of Goods Sold xxxxxxxxxxxxxxx152 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx41 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx-

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

29/02/2024

3

Hold

$3.00

5.26%

Probiotec's 1H result was in line with Morgans forecasts and company guidance. Underlying profit was $6m in a broadly flat year-on-year performance.

Indonesian-based pharmaceuticals company Pyridam is seeking to acquire Probiotec at $3.00/share. The broker notes shareholders will receive a scheme booklet in early-April and a scheme meeting is scheduled for May 29.

An interim dividend of 3cps was declared. The $3.00 target and Hold rating are maintained.

FORECAST
Morgans forecasts a full year FY24 dividend of 7.30 cents and EPS of 15.10 cents.
Morgans forecasts a full year FY25 dividend of 7.30 cents and EPS of 17.50 cents.

PBP STOCK CHART